• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2020 Fiscal Year Final Research Report

Inhibition of osteolysis by zoledronate through its action in the peripheral blood monocytes

Research Project

  • PDF
Project/Area Number 19K24103
Research Category

Grant-in-Aid for Research Activity Start-up

Allocation TypeMulti-year Fund
Review Section 0907:Oral science and related fields
Research InstitutionShowa University

Principal Investigator

Utasato Reiko (瀧本)  昭和大学, 歯学部, 助教 (00848898)

Project Period (FY) 2019-08-30 – 2021-03-31
Keywordsビスホスフォネート / ゾレドロン酸 / 破骨細胞 / 炎症性サイトカイン
Outline of Final Research Achievements

Zoledronate (ZOL) induced the expression of IRF8, a transcription factor that suppresses osteoclast differentiation, in CD14+ monocytes in human peripheral blood mononuclear cells. ZOL inhibited osteoclast differentiation from CD14+ monocytes in the presence of γδ T cells in the mononuclear cells, indicating that some femoral factors are involved in this phenomenon. We found that ZOL induced the production of TNF-α, IL-6, IL-1β, and IFN-γ by the peripheral mononuclear cells in a γδ T cell-dependent manner. These results indicate that IFN-γ is involved in the osteoclast differentiation inhibition by ZOL.

Free Research Field

口腔外科学

Academic Significance and Societal Importance of the Research Achievements

ZOLを含め、ビスホスフォネート製剤は、成熟破骨細胞に選択的に取り込まれ、その機能阻害・細胞死誘導により骨吸収を抑制する。本研究で我々は、ZOLがヒト末梢血単球の破骨細胞分化を抑制することを見出した。ZOLによる単球の破骨細胞分化抑制の機序として、単球におけるIRF8の発現誘導が示唆された。また、ZOLは末梢血単核球に作用し、IFN-γを含め種々のサイトカイン産生を高めることが示された。これは、骨吸収抑制剤ZOLの新しい作用機序と言える。

URL: 

Published: 2022-01-27  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi